Trinity Capital invests $35M in Monteris for NeuroBlate commercialization
Trinity Capital has committed $35 million in growth capital to Monteris Medical to support commercialization of its robotically controlled NeuroBlate laser therapy system. The funding will also expand Monteris’s clinical research programs targeting brain tumors, radiation necrosis and drug-resistant epilepsy.
1. Investment Commitment
Trinity Capital has allocated $35 million in growth capital to Monteris Medical, marking a strategic extension of its life sciences lending vertical. This investment underscores Trinity’s focus on high-growth MedTech firms developing innovative surgical technologies.
2. NeuroBlate System Commercialization
The funding is earmarked for the commercialization of the NeuroBlate System, a minimally invasive laser interstitial thermal therapy platform for treating brain tumors, radiation necrosis and drug-resistant epilepsy. Monteris aims to leverage the capital to expand device adoption across leading neuroscience centers.
3. Clinical Research Expansion
A portion of the capital will support multicenter studies and clinical research initiatives to generate additional prospectively published data on patient outcomes, complication rates and hospital stay durations. Enhanced clinical evidence is expected to drive broader market acceptance.
4. Implications for Trinity Capital
This deal bolsters Trinity Capital’s life sciences portfolio and showcases its tailored debt solutions for innovative companies. The partnership may contribute incremental yield and diversify the firm’s deployed capital across emerging medical technologies.